Liberate Medical Announces PREVENT Study with $6.5M Grant Funding from the US DoD – Enrolls First Patients Globally
The PREVENT study is the pivotal clinical trial of the VentFree® Respiratory Muscle Stimulator and will support FDA regulatory clearance of VentFree
CRESTWOOD, KY 9 April 2024 – Liberate Medical is proud to announce the successful commencement of patient enrollment in the PREVENT trial, a pivotal clinical trial examining the VentFree Respiratory Muscle Stimulator. PREVENT is a randomized, sham-controlled, blinded trial that aims to demonstrate that VentFree reduces the duration of invasive mechanical ventilation in acute respiratory failure patients at risk of being difficult to wean. The VentFree Respiratory Muscle Stimulator is the first and only non-invasive, breath-synchronized, neuromuscular electrical stimulator intended to reduce mechanical ventilation duration by improving expiratory muscle strength and cough. Reducing the time patients spend on mechanical ventilation should reduce the risks of prolonged mechanical ventilation, including hospital-acquired infections, deteriorated quality of life and death.
